

US 5961697 A 19991109 US 1996-727045 19961008
 US 6441141 B1 20020827 US 1999-408172 19990928
 PRAI DE 1992-4242736 A 19921217
 US 1993-166930 A3 19931215
 US 1996-727045 A3 19961008
 AB A method is described for obtaining synthetic peptides by plasmin cleavage of fibrinogen to yield C-terminal ends of the E fragment which are also antigenic. The peptides are injected into rabbits to produce antibody-producing cells which are used to generate monoclonal antibodies for use in immunoassays or in the treatment of fibrinolytic disorders.

=> d his

(FILE 'HOME' ENTERED AT 20:02:30 ON 22 JUN 2004)

FILE 'REGISTRY' ENTERED AT 20:03:02 ON 22 JUN 2004

L1 0 S C(PNDQGFSTW)(ANDGELFPESTWV)(EGKSV)(PDNDEGKSTW)(RGW)(LTKM
 L2 0 S CPGKGTLC
 L3 0 S WFCDEGPEWLFQMDG
 L4 159 S C(PNOST)(ANDGELFPESTWV)(ES)(PDNOSTY)(WILMNSTY)(FWY)/SQSP
 L5 406 S LI/SQSP

FILE 'BIOSIS, CAPUS' ENTERED AT 20:33:24 ON 22 JUN 2004

L6 103 S L4
 L7 217 S L5
 L8 296 S L6 OR L7
 L9 249 DUP REM L6 (47 DUPLICATES REMOVED)
 L10 2 S L9 AND FIBRIN (W) BIND?
 L11 92 S L9 AND PK<=2000

FILE 'REGISTRY' ENTERED AT 20:40:23 ON 22 JUN 2004

FILE 'BIOSIS, CAPUS' ENTERED AT 20:40:23 ON 22 JUN 2004

FILE 'REGISTRY' ENTERED AT 20:41:34 ON 22 JUN 2004

L12 FILE 'BIOSIS, CAPUS' ENTERED AT 20:41:35 ON 22 JUN 2004
 1 S L11 AND FIBRIN
 L13 1 S L12 NOT L10

FILE 'REGISTRY' ENTERED AT 21:03:03 ON 22 JUN 2004

L14 10 S C(PDEGM)(INDEPS)(WLT)(EC)/SQSP
 L15 28 S CDVYGTG/SQSP
 L16 5 S W(AQERX)(ALMP)CP(DEGM)(INDEPS)(WLT)(FCW)(DHES)(AGHPS)/SQSP
 L17 0 S RACPDVGTGVEL

FILE 'BIOSIS, CAPUS' ENTERED AT 21:05:00 ON 22 JUN 2004

L18 3 S L14
 L19 5 S L15
 L20 3 S L16
 L21 3 DUP REM L18 (0 DUPLICATES REMOVED)
 L22 3 DUP REM L19 (0 DUPLICATES REMOVED)
 L23 3 DUP REM L20 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 21:51:32 ON 22 JUN 2004
 341544 S C.(7)/C/SQSP

L25 5357 S C.(4)(W.(2)/C/SQSP
 L26 340 S W.(5)(ES).(1)(W.(2)/C/SQSP

FILE 'CAPUS, BIOSIS' ENTERED AT 21:53:33 ON 22 JUN 2004

L27 1663 S L25
 L28 229 S L26
 L29 1742 S L27 OR L28
 L30 1522 DUP REM L29 (220 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 21:55:31 ON 22 JUN 2004
 57517 S C.(4)(RGW).(2)/C/SQSP

FILE 'BIOSIS, CAPUS' ENTERED AT 21:56:07 ON 22 JUN 2004

FILE 'REGISTRY' ENTERED AT 21:56:28 ON 22 JUN 2004
 12975 S C.(4)(RGW).(1)(LFWY)/C/SQSP

FILE 'BIOSIS, CAPUS' ENTERED AT 21:57:25 ON 22 JUN 2004

FILE 'REGISTRY' ENTERED AT 21:57:41 ON 22 JUN 2004
 3623 S C.(2)(EGKSV).(1)(RGW).(1)(LFWY)/C/SQSP

FILE 'BIOSIS, CAPUS' ENTERED AT 21:59:05 ON 22 JUN 2004
 1479 S L23
 3 S (L30 OR L34) AND FIBRIN

=> log h

COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL
 FULL ESTIMATED COST 83.19 700.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL
 CA SUBSCRIBER PRICE -2.08 -27.72

SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 22:00:34 ON 22 JUN 2004

Second round of searching, claim 3

Connecting via Winsock to STN
 Welcome to STN International! Enter x:x

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:06:01 ON 01 OCT 2004

=> file reg SINCE FILE TOTAL
 COST IN U.S. DOLLARS ENTRY SESSION
 FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 15:06:11 ON 01 OCT 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2004 HIGHEST RN 784169-63-6
DICTIONARY FILE UPDATES: 29 SEP 2004 HIGHEST RN 784169-63-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registries.html>

=> s CPIDEGM]EINDEPS]WLT]FC/SOSP
L1 10 CPIDEGM]EINDEPS]WLT]FC/SOSP

=> FILE CAPLUS
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 0.42
TOTAL SESSION 27.97

FILE 'CAPLUS' ENTERED AT 15:07:22 ON 01 OCT 2004
US IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 30 Sep 2004 (20040930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L2 4 l1
=> dup rem l2
PROCESSING COMPLETED FOR L2
L3 4 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 bib ab 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:634089 CAPLUS
DN 141:167846

TI Binding peptides for the KDR receptor and vascular endothelial growth factor/KDR complex and their use in diagnosis, therapy, and imaging of angiogenesis-related disorders
IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert C.; Arbogast, Christopher; Bussat, Philippe; Fan, Hong; Khurana, Sucha; Linder, Karen E.; Marinelli, Edmund R.; Nanjappa, Palaniappa; Nunn, Adrian; Pillai, Radhakrishna; Pochan, Sibylla; Ramalingam, Kondaradar; Shrivastava, Ajay; Song, Bo; Swenson, Rolf E.; Von Wronski, Matthew A. PCT Int. Appl., 470 pp.
SO CODEN: PIXMD2
DT Patent
LA English
FAN CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065621	A1	20040805	WO 2003-0528787	20030911

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RW, GH, GM, KE, IS, MW, NZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GM, ML, MR, NE, SN, TD, TG

WO 2003074005 A2 20030912 WO 2003-056731 20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW, GH, GM, KE, IS, MW, NZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GM, ML, MR, NE, SN, TD, TG
PRAI US 2002-360851P P 20020301
US 2003-440411P P 20030115
US 2003-382082 A2 20030303
WO 2003-056731 A2 20030303

AB The present invention provides peptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR receptor or vascular endothelial growth factor (VEGF)/KDR complex, which have a variety of uses wherever treating, detecting, isolating, or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated peptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a $KD < 1 \text{ nmM}$), and dimer and multimeric constructs comprising these polypeptides. The involvement of VEGF and KDR

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

The present invention provides binding moieties for fibrin which have a variety of uses wherever detecting, isolating or localizing fibrin, and particularly fibrin as opposed to fibrinogen, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding fibrin and recognizing the form of polyd. fibrin found in thrombi. In addition, the polypeptides have a slow dissociation rate from fibrin, which improves their ability to form a contrast image at the site of a fibrin clot, making the disclosed binding moieties particularly useful as imaging agents for thrombi. Among examples provided are: screening of phage display libraries using the sol. fibrin-derived polypeptide DDC2 as fibrin target, and scintigraphic imaging of clots in rabbits using 99mTc-labeled peptides.

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:07:43 ON 01 OCT 2004

Third round of searching - entire claimed subject matter

```

+ + + + + STN Columbus + + + + +
FILE 'HOME' ENTERED AT 12:00:59 ON 07 OCT 2004

```

COST IN U.S. DOLLARS	
SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

Property values tagged with IC are from the ZIC/VINIT data files provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RV 757927-15-0
 TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004
 Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```

=> g
C[PENNOGSTV][ANDEGLNEPSTV][ECKSV][PDENOGKSTV][RCW][LIRNOGSTV][ILFWV]/SQSP
L1 24910 C[PENNOGSTV][ANDEGLNEPSTV][ECKSV][PDENOGKSTV][RCW][LIRNOGPESTV]
TV[ILFWV]/SQSP

```

```
=> s C[PNO$1][ANDDIGITPESTWV][ES][PDENQSTY][W][LIMNO$TV][FWY]/SQSP
L2 167 C[PNO$1][ANDDIGITPESTWV][ES][PDENQSTY][W][LIMNO$TV][FWY]/SQSP
```

```

=> 5
[CPV] [ANDEGHIILAEFSTWV] [ANOGILAEPT] C [PRIDGOFSTW] [ANQDEGILAEFSTWV] [EGKSV] [PDE
NOEGELSTV] [RGV] [LIIMNOESTV] [ILEWV] C [GGLFPRV] [PAQOLSTYDEH] [ARDILAEFWNOGSTH]/se
13 27 [CPV] [ANDEGHIILAEFSTWV] [ANOGILAEPT] C [PRIDGOFSTW] [ANQDEGILAEFSTW] [EGKSV] [PDE
TRV] [EGKSV] [PDENOEGELSTV] [RGV] [LIIMNOESTV] [ILEWV] C [GGLFPRV] [PAQ
NOGLSTYDEH] [ARDILAEFWNOGSTH]/sosp

```

```

=> S
M[ANOGEGHILNEFSWY][ANGLIMP][C][PNOST][ANDOGELMEFSWY][ES][PDENOSTY][LIMNOG
TV][FWY][C][FWY][PAGNOSTYDEH][ALIMPEWNOGSTYH]/SQP
0 M[ANOGEGHILNEFSWY][ANGLIMP][C][PNOST][ANDOGELMEFSWY][ES][
PDENOSTY][LIMNOSTY][FWY][C][FWY][PAGNOSTYDEH][ALIMPEWNOGSTYH]/SOS
P

```

```

=> S W[AOELM] [ALMP] CP [DEGMW] E [PDENS] [LT] FOW [DGHS] [AGHS] /sqsp
L5 0 W[AOELM] [ALMP] CP [DEGMW] E [PDENS] [LT] FOW [DGHS] [AGHS] /sqst

```

```
=> S W[AQELM][ALMP]CP[DEGWM]E[PDENS]LFCW[DGHS][AGHPS]/sqsp
L6      0 W[AQELM][ALMP]CP[DEGWM]E[PDENS]LFCW[DGHS][AGHPS]/sqsp
```

```
=> 5 'CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS'/SQSP
L7 2 'CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS'/SQSP
```

```
=> 5 'CYS-PRO-MET-SER-GLU-TRP-LEU-TRP-CYS' / sqsp
L8 1 'CYS-PRO-MET-SER-GLU-TRP-LEU-TRP-CYS' / sqsp
```

```

=> 5 'CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS'/sqsp
L9 5 'CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS'/sqsp

```

```

=> 3 'CYS-GLN-GLU-PRO-TRP-LEU-PHE-CYS' / sqsqp
L10 3 'CYS-GLN-GLU-GLU-PRO-TRP-LEU-PHE-CYS' / sqsqf

```

```
=> 5 'CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS'/sqsp
L11 2 'CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS'/sqsp
```

```

=> S 'CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS'//sqsp
L12 2 'CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS'//SQSP
=> S 'CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS'//sqsp
L13 2 'CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS'//SQSP
=> S 'CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS'//sqsp
L14 2 'CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS'//SQSP
=> S 'CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS'//sqsp
L15 2 'CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS'//SQSP
=> S 'CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS'//sqsp
L16 3 'CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS'//SQSP
=> S 'CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS'//sqsp
L17 2 'CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS'//SQSP
=> S 'CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS'//sqsp
L18 2 'CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS'//SQSP
=> S 'CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS'//sqsp
L19 2 'CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS'//SQSP
=> S 'CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS'//sqsp
L20 2 'CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS'//SQSP
=> S 'CYS-GLY-GLN-GLU-SER-ARG-THR-PHE-CYS'//sqsp
L21 2 'CYS-GLY-GLN-GLU-SER-ARG-THR-PHE-CYS'//SQSP
=> S 'CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS'//sqsp
L22 2 'CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS'//SQSP
=> S 'TRP-GLU-LEU-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS'//sqsp
L23 1 'TRP-GLU-LEU-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS'//SQ
SP
=> S 'TRP-MET-MET-CYS-PRO-MET-SER-GLU-TRP-LEU-TYR-CYS-TRP-SER-ALA'//sqsp
L24 1 'TRP-MET-MET-CYS-PRO-MET-SER-GLU-TRP-LEU-TYR-CYS-TRP-SER-ALA'//SQ
SP
=> S 'TRP-GLN-PRO-CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS-TRP-ASP-PRO'//sqsp
L25 4 'TRP-GLN-PRO-CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS-TRP-ASP-PRO'//SQ
SP
=> S 'TRP-ALA-PRO-CYS-GLN-GLU-GLU-PRO-TRP-LEU-PHE-CYS-PHE-HIS-GLY'//sqsp
L26 2 'TRP-ALA-PRO-CYS-GLN-GLU-GLU-PRO-TRP-LEU-PHE-CYS-PHE-HIS-GLY'//SQ
SP
=> S 'PRO-ARG-PRO-CYS-TYR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-LYS-VAL'//sqsp
L27 1 'PRO-ARG-PRO-CYS-TYR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-LYS-VAL'//SQ
SP
=> S 'PRO-ARG-PRO-CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS-GLY-PRO-ARG'//sqsp
L28 1 'PRO-ARG-PRO-CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS-GLY-PRO-ARG'//SQ
SP

```

```

=> S 'TRP-GLN-ALA-CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS-TRP-ASP-GLY'//sqsp
L29 1 'TRP-GLN-ALA-CYS-GLN-LEU-GLY-TYR-ARG-THR-TYR-CYS-TRP-ASP-GLY'//SQ
SP
=> S 'TRP-LYS-PHE-CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS-TRP-ASP-GLY'//sqsp
L30 1 'TRP-LYS-PHE-CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS-TRP-ASP-GLY'//SQ
SP
=> S 'TRP-ASN-GLY-CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS-GLY-GLU-GLY'//sqsp
L31 1 'TRP-ASN-GLY-CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS-GLY-GLU-GLY'//SQ
SP
=> S 'TRP-LEU-ASN-CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS-LEU-GLY-VAL'//sqsp
L32 1 'TRP-LEU-ASN-CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS-LEU-GLY-VAL'//SQ
SP
=> S 'CYS-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-CYS-ASP-ASP'//sqsp
L33 1 'CYS-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-CYS-ASP-ASP'//SQ
SP
=> S 'TRP-HIS-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-TRP-ALA-GLY'//sqsp
L34 1 'TRP-HIS-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-TRP-ALA-GLY'//SQ
SP
=> S 'TRP-GLN-THR-CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS-TRP-ASP-GLY'//sqsp
L35 1 'TRP-GLN-THR-CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS-TRP-ASP-GLY'//SQ
SP
=> S 'TRP-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS-PRO-ASP-GLY'//sqsp
L36 1 'TRP-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS-PRO-ASP-GLY'//SQ
SP
=> S 'PRO-ARG-PRO-CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS-TRP-GLY-GLY'//sqsp
L37 1 'PRO-ARG-PRO-CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS-TRP-GLY-GLY'//SQ
SP
=> S 'TRP-GLN-ALA-CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS-TRP-ASP-ARG'//sqsp
L38 1 'TRP-GLN-ALA-CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS-TRP-ASP-ARG'//SQ
SP
=> S 'PRO-ARG-PRO-CYS-GLY-GLN-GLU-SER-ARG-THR-PHE-CYS-LEU-GLY-GLY'//sqsp
L39 1 'PRO-ARG-PRO-CYS-GLY-GLN-GLU-SER-ARG-THR-PHE-CYS-LEU-GLY-GLY'//SQ
SP
=> S 'PRO-ARG-PRO-CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS-TRP-PRO-GLY'//sqsp
L40 1 'PRO-ARG-PRO-CYS-PHE-GLN-LYS-GLY-GLY-THR-LEU-CYS-TRP-PRO-GLY'//SQ
SP

```

```

=> log h
COST IN U.S. DOLLARS
FULL ESTIMATED COST

```

```

SESSION WILL BE HELD FOR 60 MINUTES
SIN INTERNATIONAL SESSION SUSPENDED AT 12:11:42 ON 07 OCT 2004

```

```

SINCE FILE TOTAL
ENTRY SESSION
1067.56 1067.77

```